Achievement: The Pharmaceutical Technology Innovation Center of Genertec Group Constructed by Genertec Meheco Successfully Passes Construction Phase Acceptance

On December 16, the Pharmaceutical Technology Innovation Center of Genertec Group, constructed by Genertec Meheco, successfully passed the acceptance review organized by the Group. The review panel consisted of authoritative experts from the Tianjin Institute of Industrial Biotechnology of the Chinese Academy of Sciences, Peking University, and the Academy of Military Medical Sciences. Key management from the Group, including Zhen Jing (Deputy Director of Human Resources) and Li Hanyu (Deputy General Manager of the Science, Technology, and Digitalization Department), also participated in the evaluation alongside specialists from the strategic and financial departments. Yang Guang, Chairman and Secretary of the Party Committee of Genertec Meheco, attended and addressed the meeting. Following a thorough evaluation, the expert panel reached a consensus that the Center had fulfilled all construction phase mandates and achieved its predefined objectives, passing the acceptance review. This milestone serves as both a systematic validation of the past two years of progress and a pivotal catalyst for the Center's future high-quality development. Yang Guang stated that Meheco firmly implements the CPC Central Committee's strategic directives on achieving technological self-reliance. The company has prioritized the Technology Innovation Center as its flagship initiative for corporate transformation, concentrating on chemical pharmaceuticals, green active pharmaceutical ingredients, and R&D of traditional Chinese medicine. By establishing an open collaborative R&D system ("N + 1(X) + M"), the company has made substantial progress in core technology breakthroughs, platform capacity enhancement, and high-caliber talent recruitment. This has fostered an innovation ecosystem that is clinically demand-driven and deeply integrates industry, academia, research, and application. During the review meeting, leadership and experts from Group departments provided constructive recommendations regarding platform synergy, talent structure, and project portfolio management. They underscored the imperative to enhance systemic innovation capacity, shifting from an "award-driven" approach to a "capability-driven" paradigm. They encouraged the company to expand into emerging sectors such as biologics to cultivate a "second curve" for long-term growth.